

Douglas Sato

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6078307/publications.pdf>

Version: 2024-02-01

91
papers

5,654
citations

109321

35
h-index

79698

73
g-index

93
all docs

93
docs citations

93
times ranked

4040
citing authors

#	ARTICLE	IF	CITATIONS
1	Mechanisms of myelin repair, MRI techniques and therapeutic opportunities in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 58, 103407.	2.0	5
2	Detection of MOG-IgG by cell-based assay: moving from discovery to clinical practice. <i>Neurological Sciences</i> , 2021, 42, 73-80.	1.9	14
3	Long-term safety of azathioprine for treatment of neuromyelitis optica spectrum disorders. <i>Arquivos De Neuro-Psiquiatria</i> , 2021, 79, 229-232.	0.8	5
4	Safety indicators of a novel multi supplement based on guarana, selenium, and L-carnitine: Evidence from human and red earthworm immune cells. <i>Food and Chemical Toxicology</i> , 2021, 150, 112066.	3.6	6
5	Detection of MOG-IgG in Clinical Samples by Live Cell-Based Assays: Performance of Immunofluorescence Microscopy and Flow Cytometry. <i>Frontiers in Immunology</i> , 2021, 12, 642272.	4.8	4
6	Healthy aging during the COVID-19 pandemic. <i>PAJAR - Pan-American Journal of Aging Research</i> , 2021, 9, e41087.	0.1	1
7	Status of the neuromyelitis optica spectrum disorder in Latin America. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 53, 103083.	2.0	18
8	Reduced quality of life in a pediatric-onset Neuromyelitis optica spectrum disorders cohort. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 56, 103252.	2.0	3
9	Myelin-oligodendrocyte glycoprotein antibody-associated disease. <i>Lancet Neurology</i> , The, 2021, 20, 762-772.	10.2	261
10	Decreased convulsive threshold and memory loss after anti-NMDAR positive CSF injection in zebrafish. <i>Journal of Neuroimmunology</i> , 2021, 359, 577689.	2.3	5
11	Treatment of MOG-IgG associated disease in paediatric patients: A systematic review. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 56, 103216.	2.0	10
12	Simultaneous bilateral optic neuritis and longitudinally extensive transverse myelitis following vaccination against COVID-19: A case report. <i>Neuroimmunology Reports</i> , 2021, 1, 100041.	0.4	1
13	Viral encephalitis: a practical review on diagnostic approach and treatment. <i>Jornal De Pediatria</i> , 2020, 96, 12-19.	2.0	44
14	Detection of autoantibodies in central nervous system inflammatory disorders: Clinical application of cell-based assays. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 38, 101858.	2.0	8
15	MOG-antibody-associated disease is different from MS and NMOSD and should be considered as a distinct disease entity – Yes. <i>Multiple Sclerosis Journal</i> , 2020, 26, 272-274.	3.0	18
16	Latin American consensus recommendations for management and treatment of neuromyelitis optica spectrum disorders in clinical practice. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 45, 102428.	2.0	42
17	Treatment and outcome of aquaporin-4 antibody–positive NMOSD. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	37
18	Unraveling B lymphocytes in CNS inflammatory diseases. <i>Neurology</i> , 2020, 95, 733-744.	1.1	10

#	ARTICLE	IF	CITATIONS
19	Experimental Models of Neuroimmunological Disorders: A Review. <i>Frontiers in Neurology</i> , 2020, 11, 389.	2.4	11
20	Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 44, 102251.	2.0	110
21	Characterization of pain syndromes in patients with neuromyelitis optica. <i>European Journal of Pain</i> , 2020, 24, 1548-1568.	2.8	16
22	CSF levels of glutamine synthetase and GFAP to explore astrocytic damage in seronegative NMOSD. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 605-611.	1.9	17
23	Treatment of MOG antibody associated disorders: results of an international survey. <i>Journal of Neurology</i> , 2020, 267, 3565-3577.	3.6	64
24	Viral encephalitis: a practical review on diagnostic approach and treatment. <i>Jornal De Pediatria (Versão Em Português)</i> , 2020, 96, 12-19.	0.2	7
25	Role of Glutamatergic Excitotoxicity in Neuromyelitis Optica Spectrum Disorders. <i>Frontiers in Cellular Neuroscience</i> , 2019, 13, 142.	3.7	19
26	Persistent MOG-IgG positivity is a predictor of recurrence in MOG-IgG-associated optic neuritis, encephalitis and myelitis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1907-1914.	3.0	45
27	Clinical spectrum of inflammatory central nervous system demyelinating disorders associated with antibodies against myelin oligodendrocyte glycoprotein. <i>Neurochemistry International</i> , 2019, 130, 104319.	3.8	35
28	Correlation between the corpus callosum index and brain atrophy, lesion load, and cognitive dysfunction in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 20, 154-158.	2.0	20
29	Myelin oligodendrocyte glycoprotein immunoglobulin G-associated disease: An overview. <i>Clinical and Experimental Neuroimmunology</i> , 2018, 9, 48-55.	1.0	13
30	Brazilian Consensus for the Treatment of Multiple Sclerosis: Brazilian Academy of Neurology and Brazilian Committee on Treatment and Research in Multiple Sclerosis. <i>Arquivos De Neuro-Psiquiatria</i> , 2018, 76, 539-554.	0.8	22
31	Consensus recommendations for the diagnosis and treatment of primary progressive multiple sclerosis in Latin America. <i>Journal of the Neurological Sciences</i> , 2018, 393, 4-13.	0.6	7
32	MOG-IgG-Associated Optic Neuritis, Encephalitis, and Myelitis: Lessons Learned From Neuromyelitis Optica Spectrum Disorder. <i>Frontiers in Neurology</i> , 2018, 9, 217.	2.4	156
33	CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 927-936.	1.9	116
34	MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e322.	6.0	334
35	Bilateral frontal cortex encephalitis and paraparesis in a patient with anti-MOG antibodies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 534-536.	1.9	113
36	Neuromyelitis Optica Spectrum Disorders. <i>Neuroimaging Clinics of North America</i> , 2017, 27, 251-265.	1.0	53

#	ARTICLE	IF	CITATIONS
37	Autoimmune encephalitis in patients with anti-myelin oligodendrocyte glycoprotein-antibody. Journal of the Neurological Sciences, 2017, 381, 792.	0.6	0
38	Discrimination of spinal cord sarcoidosis from neuromyelitis optica spectrum disorder or spondylotic myelopathy. Journal of the Neurological Sciences, 2017, 381, 449-450.	0.6	0
39	MOG-IgG associated optic neuritis is not multiple sclerosis. Arquivos De Neuro-Psiquiatria, 2017, 75, 687-691.	0.8	8
40	Quality of life goes beyond the medical priorities in multiple sclerosis: assessing the impact of social support network. Arquivos De Neuro-Psiquiatria, 2017, 75, 263-264.	0.8	0
41	Isolated rhombencephalitis with good clinical recovery. Arquivos De Neuro-Psiquiatria, 2017, 75, 757-757.	0.8	0
42	Th17 Cells Pathways in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders: Pathophysiological and Therapeutic Implications. Mediators of Inflammation, 2016, 2016, 1-11.	3.0	92
43	Relapsing optic neuritis and isolated transverse myelitis are the predominant clinical phenotypes for patients with antibodies to myelin oligodendrocyte glycoprotein in India. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2016, 2, 205521731667563.	1.0	15
44	A Regional Analysis of Relapsing Remitting MS (RRMS) Patients Treated with Natalizumab Suggests a Need to Diagnose and Treat Early in Latin Americans. Value in Health, 2016, 19, A437.	0.3	0
45	Lesion length of optic neuritis impacts visual prognosis in neuromyelitis optica. Journal of Neuroimmunology, 2016, 293, 28-33.	2.3	81
46	Different etiologies and prognoses of optic neuritis in demyelinating diseases. Journal of Neuroimmunology, 2016, 299, 152-157.	2.3	63
47	Myelin injury without astrocytopathy in neuroinflammatory disorders with MOG antibodies. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1257-1259.	1.9	89
48	Post-vaccination MDEM associated with MOG antibody in a subclinical Chlamydia infected boy. Brain and Development, 2016, 38, 690-693.	1.1	19
49	The clinical spectrum associated with myelin oligodendrocyte glycoprotein antibodies (anti-MOG-Ab) in Thai patients. Multiple Sclerosis Journal, 2016, 22, 964-968.	3.0	31
50	MRI and retinal abnormalities in isolated optic neuritis with myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies: a comparative study: Table A1. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 446-448.	1.9	134
51	Time to target brain atrophy and neurodegeneration in multiple sclerosis. Arquivos De Neuro-Psiquiatria, 2016, 74, 181-182.	0.8	2
52	Serological markers associated with neuromyelitis optica spectrum disorders in South India. Annals of Indian Academy of Neurology, 2016, 19, 505.	0.5	24
53	Sometimes less is more in multiple sclerosis drug switching. Arquivos De Neuro-Psiquiatria, 2016, 74, 605-606.	0.8	0
54	2014 Joint Americas Committee for Treatment and Research in Multiple Sclerosisâ€“European Committee for Treatment and Research in Multiple Sclerosis Meeting. Clinical and Experimental Neuroimmunology, 2015, 6, 100-102.	1.0	0

#	ARTICLE	IF	CITATIONS
55	Leukoencephalopathy resolution after atypical mycobacterial treatment: a case report. <i>BMC Neurology</i> , 2015, 15, 159.	1.8	1
56	Severely exacerbated neuromyelitis optica rat model with extensive astrocytopathy by high affinity anti-aquaporin-4 monoclonal antibody. <i>Acta Neuropathologica Communications</i> , 2015, 3, 82.	5.2	54
57	Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder. <i>JAMA Neurology</i> , 2015, 72, 815.	9.0	59
58	Highly encephalitogenic aquaporin 4-specific T cells and NMO-IgG jointly orchestrate lesion location and tissue damage in the CNS. <i>Acta Neuropathologica</i> , 2015, 130, 783-798.	7.7	55
59	Fulminant demyelinating encephalomyelitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e175.	6.0	75
60	Idiopathic aquaporin-4 antibody negative longitudinally extensive transverse myelitis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 710-717.	3.0	25
61	Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography. <i>Multiple Sclerosis Journal</i> , 2015, 21, 678-688.	3.0	209
62	Clinical features and long-term outcome of a group of Japanese children with inflammatory central nervous system disorders and seropositivity to myelin-oligodendrocyte glycoprotein antibodies. <i>Brain and Development</i> , 2015, 37, 849-852.	1.1	30
63	Demographic and clinical features of neuromyelitis optica: A review. <i>Multiple Sclerosis Journal</i> , 2015, 21, 845-853.	3.0	278
64	MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e89.	6.0	322
65	MRI characteristics of neuromyelitis optica spectrum disorder. <i>Neurology</i> , 2015, 84, 1165-1173.	1.1	523
66	Update on biomarkers in neuromyelitis optica. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e134.	6.0	104
67	Anti-MOG (Myelin Oligodendrocyte Glycoprotein)â€“Positive Severe Optic Neuritis with Optic Disc Ischaemia and Macular Star. <i>Neuro-Ophthalmology</i> , 2015, 39, 285-288.	1.0	12
68	MOG-IgG serological status matters in paediatric ADEM. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 242-242.	1.9	8
69	Severe demyelination but no astrocytopathy in clinically definite neuromyelitis optica with anti-myelin-oligodendrocyte glycoprotein antibody. <i>Multiple Sclerosis Journal</i> , 2015, 21, 656-659.	3.0	63
70	Seronegative Neuromyelitis Optica Spectrum - The challenges on disease definition and pathogenesis. <i>Arquivos De Neuro-Psiquiatria</i> , 2014, 72, 445-450.	0.8	25
71	Influenza-associated MOG antibody-positive longitudinally extensive transverse myelitis: a case report. <i>BMC Neurology</i> , 2014, 14, 224.	1.8	40
72	Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. <i>Neurology</i> , 2014, 82, 474-481.	1.1	743

#	ARTICLE	IF	CITATIONS
73	Aquaporin-4 antibody-positive myelitis initially biopsied for suspected spinal cord tumors: Diagnostic considerations. <i>Multiple Sclerosis Journal</i> , 2014, 20, 621-626.	3.0	10
74	Anti-N-methyl-D-aspartate receptor encephalitis with multiphasic demyelination. <i>Annals of Neurology</i> , 2014, 76, 462-464.	5.3	18
75	Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. <i>Neurology</i> , 2014, 83, 1122-1123.	1.1	17
76	Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. <i>Neurology</i> , 2014, 83, 475-476.	1.1	16
77	Aquaporin-4 antibody-positive cases beyond current diagnostic criteria for NMO spectrum disorders. <i>Neurology</i> , 2014, 82, 372-372.	1.1	1
78	Cerebrospinal fluid aquaporin-4 antibody levels in neuromyelitis optica attacks. <i>Annals of Neurology</i> , 2014, 76, 305-309.	5.3	49
79	Changes in Th17 and regulatory T cells after fingolimod initiation to treat multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2014, 268, 95-98.	2.3	50
80	Case of autoantibodies against N-methyl-D-aspartate receptor+/antibodies against myelin oligodendrocyte glycoprotein+ multiphasic acute disseminated encephalomyelitis (ADEM). <i>Clinical and Experimental Neuroimmunology</i> , 2014, 5, 49-51.	1.0	3
81	Oral fingolimod to treat multiple sclerosis: see your cardiologist first. <i>Arquivos De Neuro-Psiquiatria</i> , 2014, 72, 651-652.	0.8	2
82	Clinical Spectrum and Treatment of Neuromyelitis Optica Spectrum Disorders: Evolution and Current Status. <i>Brain Pathology</i> , 2013, 23, 647-660.	4.1	36
83	Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 922-930.	1.9	149
84	AQP4 antibody serostatus. <i>Neurology</i> , 2013, 81, 1186-1188.	1.1	12
85	Aquaporin-4 antibody-positive cases beyond current diagnostic criteria for NMO spectrum disorders. <i>Neurology</i> , 2013, 80, 2210-2216.	1.1	98
86	Neutralizing Antibodies Are Associated with a Reduction of Interferon- β Efficacy during the Treatment of Japanese Multiple Sclerosis Patients. <i>Tohoku Journal of Experimental Medicine</i> , 2012, 228, 85-92.	1.2	14
87	Treatment of neuromyelitis optica: an evidence based review. <i>Arquivos De Neuro-Psiquiatria</i> , 2012, 70, 59-66.	0.8	43
88	Myasthenia gravis and neuromyelitis optica spectrum disorder. <i>Neurology</i> , 2012, 78, 1601-1607.	1.1	177
89	Neuromyelitis optica should be classified as an astrocytopathic disease rather than a demyelinating disease. <i>Clinical and Experimental Neuroimmunology</i> , 2012, 3, 58-73.	1.0	79
90	Atypical presentations of neuromyelitis optica. <i>Arquivos De Neuro-Psiquiatria</i> , 2011, 69, 824-828.	0.8	29

#	ARTICLE	IF	CITATIONS
91	Neuromyelitis optica without typical opticospinal phenotype. Multiple Sclerosis Journal, 2010, 16, 1154-1155.	3.0	9